This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4 Oct 2011

Rexahn Completes Patient Recruitment in Cancer Drug Trial

Rexahn Pharmaceuticals has completed enrollment for a Phase II clinical trial of its experimental cancer drug Archexin.

US-based clinical stage pharmaceutical company Rexahn Pharmaceuticals has announced the completion of patient enrollment in its Phase II clinical trial designed to investigate the ability of Archexinin to treat metastatic pancreatic cancer. The company expects to report preliminary results in the first half of 2012.


The two-stage, single arm, open label study in combination with gemcitabine enrolled approximately 35 patients to evaluate the overall survival rate of the patients treated with the drug candidate.


Archexin, an Akt protein kinase inhibitor, inhibits cancer cell survival and proliferation, angiogenesis and drug resistance.


Phase I clinical trial data has shown that Archexin has a human saf

Related News